Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

International Conference on Reliability, Infocom Technologies and Optimization (Trends and Future Directions) (ICRITO)

Quantum-Enhanced Conditional GAN for Targeted Molecule Design

Aakanksha Baidya, Manish Pratap Singh, Sanjay Kumar Dubey

Published Sep 18, 2025• 0 citations
Publisher

Abstract

Drug discovery for a given protein target is a complex, resource-intensive process, often requiring years of research and billions of dollars in investment. Computational techniques, particularly deep learning models, have accelerated molecular generation, but they remain constrained by classical computational limitations and reliance on known chemical patterns. To address these challenges, we propose a hybrid quantum conditional GAN with gradient penalty for drug design, integrating quantum computing to enhance exploration of the vast chemical space. The proposed approach leverages a hybrid classical and quantum generative model to create novel molecular structures while ensuring they adhere to chemical and pharmacological properties. By conditioning the generative model on protein target sequences, we improve molecular specificity, increasing the likelihood of discovering viable drug candidates. Our framework generates chemically valid, diverse, and target-specific molecules, offering a promising avenue for more efficient and precise data-driven drug discovery.

DOI
10.1109/icrito66076.2025.11241874

Related papers

Quantum Generative Models for Small Molecule Drug Discovery

Junde Li, Rasit Onur Topaloglu, Swaroop Ghosh

Existing drug discovery pipelines take 5–10 years and cost billions of dollars. Computational approaches aim to sample from regions of the whole molecular and solid-state compounds called chemical space, which could be on the order of$10^{60}$. Deep generative models can model the underlying probability distribution of both the physical structures and property of drugs and relate them nonlinearly. By exploiting patterns in massive datasets, these models can distill salient features that characterize the molecules. Generative adversarial networks (GANs) discover drug candidates by generating molecular structures that obey chemical and physical properties and show affinity toward binding with the receptor for a target disease. However, classical GANs cannot explore certain regions of the chemical space and suffer from training instabilities. The practical utility of such models is limited due to the vast size of the search space, characterized by millions of parameters. A full quantum GAN may require more than 90 qubits even to generate small molecules with up to nine heavy atoms. The proposed quantum GAN with a hybrid generator (QGAN-HG) model is composed of a hybrid quantum generator that supports various number of qubits and quantum circuit layers, and a classical discriminator. The QGAN-HG with less than 20% of the original parameters can learn molecular distributions as efficiently as its classical counterpart. Another extended version of the proposed QGAN-HG, which utilizes multiple quantum subcircuits, considerably accelerates our standard QGAN-HG training process and avoids the potential gradient vanishing issue of deep neural networks.

arXiv:2101.03438•IEEE Transactions on Quantum Engineering•Jan 1, 2021•121 citations

Invited: Drug Discovery Approaches using Quantum Machine Learning

Junde Li, Mahabubul Alam, Congzhou Mike Sha +3 more

Traditional drug discovery pipelines can require multiple years and billions of dollars of investment. Deep generative and discriminative models are widely adopted to assist in drug development. Classical machines cannot efficiently reproduce the atypical patterns of quantum computers, which may improve the quality of learned tasks. We propose a suite of quantum machine learning techniques: incorporating generative adversarial networks (GAN), convolutional neural networks (CNN) and variational auto-encoders (VAE) to generate small drug molecules, classify binding pockets in proteins, and generate large drug molecules, respectively.

ACM/IEEE Design Automation Conference (DAC)•Nov 8, 2021•34 citations

MolGAN-QRL: a hybrid framework for molecule generation using quantum-enhanced reinforcement learning

Mohamed Iheb Hergli, Emna Harigua‐Souiai

Discovering novel drug candidates remains a considerable challenge in pharmaceutical research. Generative AI models such as Generative Adversarial Networks (GANs) have shown considerable promise in de novo molecular generation. They demonstrated high potential in drug discovery applications, yet they often face challenges such as limited chemical coverage and mode collapse. In the present study, we developed MolGAN-QRL, a hybrid quantum-classical framework that introduced quantum-enhanced reinforcement learning within the MolGAN architecture to address these limitations. The proposed framework leveraged a hybrid reward mechanism to further optimize chemical validity, uniqueness, and drug-likeliness of the generated molecules. Experimental results demonstrated that MolGAN-QRL consistently achieved enhanced generative performances compared to classical MolGAN, with up to a 16-fold increase in the count of unique and valid generated compounds under certain conditions. These gains reflected the effectiveness of quantum-guided exploration and highlighted the known trade-off between uniqueness and validity in generative chemistry. Overall, our findings underlined the value of quantum-enhanced reward modeling in mitigating mode collapse and advancing molecular generation, and support the potential of hybrid quantum-classical methods to advance generative chemistry for drug discovery applications. SCIENTIFIC CONTRIBUTION: MolGAN-QRL introduces the first variant of the MolGAN framework, that is augmented with a variational quantum circuit (VQC) within the reinforcement-learning reward module, rather than the generator, the discriminator or the noise function. It leverages a hybrid reward mechanism that trains a quantum-classical function that lead to better mitigation of mode-collapse, through higher uniqueness scores and 16-fold more novel, valid and unique molecules generated.

Journal of Cheminformatics•Feb 2, 2026•1 citation

Quantum Generative Adversarial Networks for Drug Discovery – Molecular Representation Learning

Jincheng Zhang

Drug discovery is a notoriously lengthy, costly, and often unsuccessful process. Traditional methods rely heavily on high-throughput screening and iterative optimization, which are computationally intensive and time-consuming. This research investigates the potential of Quantum Generative Adversarial Networks (QGANs) to significantly accelerate this process by learning efficient molecular representations and generating novel drug candidates. QGANs utilize quantum superposition to explore a vast chemical space, offering a fundamentally different approach compared to classical generative models. We propose a framework where a quantum generator network learns to create molecular structures, while a classical discriminator network evaluates their properties against desired criteria. The core innovation lies in the application of quantum computing principles to molecular representation learning, aiming to drastically reduce the computational burden associated with generating and evaluating potential drug candidates. The resulting molecular representations are then used to guide the generation of new compounds with optimized characteristics, addressing a critical bottleneck in the drug discovery pipeline. The framework presented herein provides a theoretical foundation and outlines a potential approach for leveraging quantum computing to revolutionize drug discovery.

•Sep 4, 2026•0 citations

Hybrid Quantum-Classical Generative Adversarial Network for synthesizing chemically feasible molecules

Diptanshu Sikdar, Max Cui, Adelina Chau +3 more

Current drug discovery processes can cost billions of dollars and usually take five to ten years. People have been researching and implementing various computational approaches to search for molecules and compounds from the chemical space, which can be on the order of 1060 molecules. One solution involves deep generative models, which are artificial intelligence models that learn from nonlinear data by modeling the probability distribution of chemical structures and creating similar data points from the trends it identifies. These generative models can extract salient features that characterize the molecules. However, they often suffer from increased time complexity. Aiming for faster runtime and greater robustness when analyzing high-dimensional data, we designed and implemented a Hybrid Quantum-Classical Generative Adversarial Network (QGAN) to synthesize molecules. There are two parts in the QGAN: a quantum generator that creates molecules based on the probability distributions of likely combinations and a classical discriminator that differentiates real molecules from the generated ones. We hypothesized that a quantum generator would be more impactful, offering a runtime speedup and increasing generated molecule possibilities, because we could use quantum mechanical phenomena superposition, entanglement, and interference to analyze more atom-bond combinations than a classical generator. The PyTorch-PennyLane implementation of the QGAN generated seven chemically stable molecules out of 300, a 2.3% success rate. Although the QGAN is a work in progress, it has demonstrated a path towards more efficient drug development, which would accelerate the development of medicines and reduce costs for the whole R&D process.

Journal of Emerging Investigators•Jan 1, 2023•2 citations

Quantum-Enhanced Computational Drug Discovery: Leveraging Variational Quantum Algorithms for Accurate Binding Affinity Prediction and Lead Optimization in Complex Biological Targets

Hande Selvi Yanık

Accurate prediction of binding affinities and efficient lead optimization remain central challenges in computational drug discovery, particularly for complex biological targets characterized by rugged energy landscapes, conformational heterogeneity, and high-dimensional interaction spaces. Classical computational methods—such as molecular docking, force-field–based simulations, and deep learning models—have made substantial progress, yet they often struggle to capture quantum-mechanical effects and long-range correlations critical to molecular recognition. This study explores a quantum-enhanced framework that integrates Variational Quantum Algorithms (VQAs), quantum-inspired Hamiltonian modeling, and hybrid quantum–classical optimization workflows to improve the fidelity and scalability of drug discovery pipelines. By encoding molecular interactions into parameterized quantum circuits, the framework leverages quantum superposition and entanglement to explore complex chemical space more efficiently, enabling refined estimation of binding energies and accelerated identification of high-quality leads. Preliminary simulations indicate that VQA-based estimators outperform classical baselines for challenging protein–ligand systems, reducing prediction error while maintaining computational tractability. These findings highlight the emerging potential of quantum technologies to enable more accurate, data-efficient, and mechanistically grounded drug discovery for next-generation therapeutics.

Next frontier.•Nov 28, 2025•0 citations
Drug discovery for a given protein target is a complex, resource-intensive process, often requiring years of research and billions of dollars in investment. Computational techniques, particularly deep learning models, have accelerated molecular generation, but they remain constrained by classical computational limitations and reliance on known chemical patterns. To address these challenges, we propose a hybrid quantum conditional GAN with gradient penalty for drug design, integrating quantum computing to enhance exploration of the vast chemical space. The proposed approach leverages a hybrid classical and quantum generative model to create novel molecular structures while ensuring they adhere to chemical and pharmacological properties. By conditioning the generative model on protein target sequences, we improve molecular specificity, increasing the likelihood of discovering viable drug candidates. Our framework generates chemically valid, diverse, and target-specific molecules, offering a promising avenue for more efficient and precise data-driven drug discovery.
Existing drug discovery pipelines take 5–10 years and cost billions of dollars. Computational approaches aim to sample from regions of the whole molecular and solid-state compounds called chemical space, which could be on the order of106010^{60}1060. Deep generative models can model the underlying probability distribution of both the physical structures and property of drugs and relate them nonlinearly. By exploiting patterns in massive datasets, these models can distill salient features that characterize the molecules. Generative adversarial networks (GANs) discover drug candidates by generating molecular structures that obey chemical and physical properties and show affinity toward binding with the receptor for a target disease. However, classical GANs cannot explore certain regions of the chemical space and suffer from training instabilities. The practical utility of such models is limited due to the vast size of the search space, characterized by millions of parameters. A full quantum GAN may require more than 90 qubits even to generate small molecules with up to nine heavy atoms. The proposed quantum GAN with a hybrid generator (QGAN-HG) model is composed of a hybrid quantum generator that supports various number of qubits and quantum circuit layers, and a classical discriminator. The QGAN-HG with less than 20% of the original parameters can learn molecular distributions as efficiently as its classical counterpart. Another extended version of the proposed QGAN-HG, which utilizes multiple quantum subcircuits, considerably accelerates our standard QGAN-HG training process and avoids the potential gradient vanishing issue of deep neural networks.
Traditional drug discovery pipelines can require multiple years and billions of dollars of investment. Deep generative and discriminative models are widely adopted to assist in drug development. Classical machines cannot efficiently reproduce the atypical patterns of quantum computers, which may improve the quality of learned tasks. We propose a suite of quantum machine learning techniques: incorporating generative adversarial networks (GAN), convolutional neural networks (CNN) and variational auto-encoders (VAE) to generate small drug molecules, classify binding pockets in proteins, and generate large drug molecules, respectively.
Discovering novel drug candidates remains a considerable challenge in pharmaceutical research. Generative AI models such as Generative Adversarial Networks (GANs) have shown considerable promise in de novo molecular generation. They demonstrated high potential in drug discovery applications, yet they often face challenges such as limited chemical coverage and mode collapse. In the present study, we developed MolGAN-QRL, a hybrid quantum-classical framework that introduced quantum-enhanced reinforcement learning within the MolGAN architecture to address these limitations. The proposed framework leveraged a hybrid reward mechanism to further optimize chemical validity, uniqueness, and drug-likeliness of the generated molecules. Experimental results demonstrated that MolGAN-QRL consistently achieved enhanced generative performances compared to classical MolGAN, with up to a 16-fold increase in the count of unique and valid generated compounds under certain conditions. These gains reflected the effectiveness of quantum-guided exploration and highlighted the known trade-off between uniqueness and validity in generative chemistry. Overall, our findings underlined the value of quantum-enhanced reward modeling in mitigating mode collapse and advancing molecular generation, and support the potential of hybrid quantum-classical methods to advance generative chemistry for drug discovery applications. SCIENTIFIC CONTRIBUTION: MolGAN-QRL introduces the first variant of the MolGAN framework, that is augmented with a variational quantum circuit (VQC) within the reinforcement-learning reward module, rather than the generator, the discriminator or the noise function. It leverages a hybrid reward mechanism that trains a quantum-classical function that lead to better mitigation of mode-collapse, through higher uniqueness scores and 16-fold more novel, valid and unique molecules generated.
Drug discovery is a notoriously lengthy, costly, and often unsuccessful process. Traditional methods rely heavily on high-throughput screening and iterative optimization, which are computationally intensive and time-consuming. This research investigates the potential of Quantum Generative Adversarial Networks (QGANs) to significantly accelerate this process by learning efficient molecular representations and generating novel drug candidates. QGANs utilize quantum superposition to explore a vast chemical space, offering a fundamentally different approach compared to classical generative models. We propose a framework where a quantum generator network learns to create molecular structures, while a classical discriminator network evaluates their properties against desired criteria. The core innovation lies in the application of quantum computing principles to molecular representation learning, aiming to drastically reduce the computational burden associated with generating and evaluating potential drug candidates. The resulting molecular representations are then used to guide the generation of new compounds with optimized characteristics, addressing a critical bottleneck in the drug discovery pipeline. The framework presented herein provides a theoretical foundation and outlines a potential approach for leveraging quantum computing to revolutionize drug discovery.
Current drug discovery processes can cost billions of dollars and usually take five to ten years. People have been researching and implementing various computational approaches to search for molecules and compounds from the chemical space, which can be on the order of 1060 molecules. One solution involves deep generative models, which are artificial intelligence models that learn from nonlinear data by modeling the probability distribution of chemical structures and creating similar data points from the trends it identifies. These generative models can extract salient features that characterize the molecules. However, they often suffer from increased time complexity. Aiming for faster runtime and greater robustness when analyzing high-dimensional data, we designed and implemented a Hybrid Quantum-Classical Generative Adversarial Network (QGAN) to synthesize molecules. There are two parts in the QGAN: a quantum generator that creates molecules based on the probability distributions of likely combinations and a classical discriminator that differentiates real molecules from the generated ones. We hypothesized that a quantum generator would be more impactful, offering a runtime speedup and increasing generated molecule possibilities, because we could use quantum mechanical phenomena superposition, entanglement, and interference to analyze more atom-bond combinations than a classical generator. The PyTorch-PennyLane implementation of the QGAN generated seven chemically stable molecules out of 300, a 2.3% success rate. Although the QGAN is a work in progress, it has demonstrated a path towards more efficient drug development, which would accelerate the development of medicines and reduce costs for the whole R&D process.
Accurate prediction of binding affinities and efficient lead optimization remain central challenges in computational drug discovery, particularly for complex biological targets characterized by rugged energy landscapes, conformational heterogeneity, and high-dimensional interaction spaces. Classical computational methods—such as molecular docking, force-field–based simulations, and deep learning models—have made substantial progress, yet they often struggle to capture quantum-mechanical effects and long-range correlations critical to molecular recognition. This study explores a quantum-enhanced framework that integrates Variational Quantum Algorithms (VQAs), quantum-inspired Hamiltonian modeling, and hybrid quantum–classical optimization workflows to improve the fidelity and scalability of drug discovery pipelines. By encoding molecular interactions into parameterized quantum circuits, the framework leverages quantum superposition and entanglement to explore complex chemical space more efficiently, enabling refined estimation of binding energies and accelerated identification of high-quality leads. Preliminary simulations indicate that VQA-based estimators outperform classical baselines for challenging protein–ligand systems, reducing prediction error while maintaining computational tractability. These findings highlight the emerging potential of quantum technologies to enable more accurate, data-efficient, and mechanistically grounded drug discovery for next-generation therapeutics.